Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30748791 | 1.00 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3MAOBHRH3 | |
| SCHEMBL19384481 | 0.90 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3MAOBHRH3 | |
| SCHEMBL19384485 | 0.90 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3MAOBHRH3 | |
| SCHEMBL19384222 | 0.90 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3MAOBHRH3 | |
| SCHEMBL29711702 | 0.87 | SLC6A4 (0.67) | SLC6A2SLC6A4SLC6A3MAOBHRH1 | |
| SCHEMBL1416985 | 0.87 | SLC6A4 (0.67) | SLC6A2SLC6A4SLC6A3MAOBHRH1 | |
| SCHEMBL29735165 | 0.84 | SLC6A4 (0.63) | SLC6A2SLC6A4SLC6A3MAOBHRH1 | |
| SCHEMBL1438129 | 0.84 | SLC6A4 (0.63) | SLC6A2SLC6A4SLC6A3MAOBHRH1 | |
| SCHEMBL30124975 | 0.84 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3MAOBHRH1 | |
| SCHEMBL1337657 | 0.84 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3MAOBHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206758-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| US-20210206758-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| EP-3433254-B1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-17 | — | — | EP | disclosed |
| EP-3433254-B1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-17 | — | — | EP | disclosed |
| EP-3209664-B1 | BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20190112306-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
| US-20190112306-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
| EP-3433255-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-01-30 | — | — | EP | disclosed |
| EP-3433254-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-01-30 | — | — | EP | disclosed |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| WO-2017162570-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162572-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162570-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206758-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | ITGB6, ITGA6, ITGB3 | SLC6A2 500/4885SLC6A4 1457/4885SLC6A3 1081/4885 |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | PIK3R3, JAK2, JAK3 | SLC6A2 3622/4885SLC6A4 2991/4885SLC6A3 1069/4885 |
| US-20190112306-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | ITGB6, ITGA6, GP6 | SLC6A2 531/4885SLC6A4 1492/4885SLC6A3 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.